Collectively, these findings describe the power of EBNA1 IgM to discriminate RA-positive individuals from individuals with SLE and HCs, which ultimately may contribute to the generation of new and simplified diagnostic assays. This evidence concerns the gene CD40LG and rheumatoid arthritis.